Search
Feed aggregator
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data 4/5/2024
Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B
Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B 4/30/2024
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer 4/30/2024
Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group
Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group 4/30/2024
J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program
J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program 4/30/2024
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win 4/30/2024
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership 4/30/2024
Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique
Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique 4/30/2024
A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach
A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach 4/30/2024
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint 4/29/2024
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases 4/29/2024
FDA Approves First Targeted Treatment for WHIM Syndrome
FDA Approves First Targeted Treatment for WHIM Syndrome 4/29/2024
J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate
J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate 4/29/2024
Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study
Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study 4/29/2024
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT 4/29/2024
Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report
Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report 4/29/2024
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss 4/29/2024
As Autism Cases Rise, Biopharma Springs Into Action
As Autism Cases Rise, Biopharma Springs Into Action 4/29/2024
5 Mid-Stage ALS Drugs to Watch
5 Mid-Stage ALS Drugs to Watch 4/29/2024
Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia
Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia 4/29/2024
World Pharma News
- Next-generation microbiome medicine may revolutionize the treatment of Parkinson's and similar disorders
- A cellular protein, FGD3, boosts breast cancer chemotherapy, immunotherapy
- Common gout drug may reduce risk of heart attack and stroke
- New nasal vaccine has potential to transform respiratory disease prevention
- MIT research finds particles that enhance mRNA delivery could reduce vaccine dosage and costs